TRAI — Research — Healthcare (TMO, ISRG, JNJ)

← Research · knowledge/sectors/healthcare.md

_Last updated 2026-11-06 09:00 ET from report. Screening/research, not investment advice._

TMO — life-science tools and services. ISRG — robotic surgery. JNJ — pharma + MedTech. Others in TRAI's pharma cluster 3: GILD, BMY, LLY, ABBV, VRTX, PFE, AMGN (avg ρ 0.567).

Weak within the sector: TRAI Healthcare intra-sector ρ 0.32; TMO–ISRG 0.20, TMO–JNJ 0.08, ISRG–JNJ 0.33. TMO and ISRG are singletons (49, 45). ISRG–BX 0.51.
Defensive mirror of the AI trade: JNJ–GEV −0.49.
TRAI's clusterFlag still tags ISRG and JNJ "Healthcare ×2" (S-023).

2026-10-13: JNJ Q3 (gap −3.48%, close-to-close −5.73%) (TRAI).
2026-10-20: ISRG Q3 AMC: revenue $3.05B (+22%), procedures +15%, $450M antitrust charge (ISRG IR); gap −8.11%, day-1 +6.37% (TRAI).
2026-10-21: TMO Q3: revenue $12.14B (+9%), adj. EPS $6.68 (TMO IR); gap −3.25%, day-1 +4.36% (TRAI).
2026-10-22: JNJ +3.81% on VARIPULSE Pro / Omny-IRE electrophysiology data (Investing.com); ISRG +3.67%; TMO −2.52% (TRAI).
2026-10-23 (12:05 ET): XLV −0.96%; TMO −1.45%, ISRG +2.59%, JNJ −1.74% (Yahoo).

ISRG next print 2027-01-21 (TRAI). TMO and JNJ show next = null (data gap, S-008).

TMO avg |gap| 5.98% (2.17 ATR); ISRG 5.1%; JNJ 2.38% (fill 75%). Recent prints in all three gapped down and then rallied on day 1 (TMO, ISRG) — post-print drift is unpredictable at n = 4.

GILD beat and raised after the close (FY product sales $31.0–31.3B), +2.2% after hours, while the postclose run lists it as a mean_reversion fade-short (S-071). ABBV (cluster 3, GILD ρ 0.59) and REGN report Fri BMO; ABBV gapped down on its last 4 prints. GILD · ABBV · REGN
Source: 2026-10-29 17:00 report.

Healthcare is the bid sector in a tech/crypto rotation: REGN +6.9% (beat, Sanofi deal), LLY/AMGN/MRK +2.6–2.9% (TRAI 8:53), ABBV −0.3% (in-line raise). GILD +4.76% after its beat-and-raise and five PT hikes, yet the MR bucket still lists it as a fade-short → S-077. GILD · REGN · ABBV
Source: 2026-10-30 09:00 — premarket rotation, INTC/crypto shocks, BMO prints.

10-30 ~10:13 ET: pharma cluster 3 is bid across the board: LLY +4.1% (day 2 of a beat-and-raise, FY26 revenue guide $91–92B; LLY note), GILD +4.5%, BMY +3.0%, VRTX +2.8%, MRK +2.4%, AMGN +2.0%, ABBV +1.8% (it was −0.4% premarket); REGN +12.0% (own print, 09:00 report). XLV +1.35%.
Upcoming: VRTX 11-02 AMC; PFE 11-03 BMO; AMGN 11-03 AMC; CVS and NVO 11-04 BMO; MRNA 11-06 BMO (TRAI /api/events).
2026-10-30 10:00 — open follow-through, telecom/pharma bid, software split

VRTX prints Mon 11-02 AMC (avg |gap| 0.95%, smallest of the Monday set); povetacicept PDUFA 2026-11-30. VRTX +3.4% at 12:02 ET with the defensive pharma bid. AMGN (ρ 0.65) and PFE (0.63) report Tue 11-03.
2026-10-30 12:00 — Monday AMC prints

REGN day 2: +3.6% vs prior close at 11:15 ET on ≥ 4 analyst price-target raises, while XBI −2.4%, IBB −1.5%, GILD −1.8%, LLY −0.9%, AMGN −0.9%, VRTX +0.2% (Yahoo, unofficial). XBI's cause: unknown (no single source). Details in the REGN note.
Print cluster: VRTX tonight AMC (call 4:30 PM ET; Vertex IR); PFE Tue BMO; AMGN Tue AMC; NVO and CVS Wed BMO; MRNA Fri BMO (/api/events). These are REGN's top-ρ peers (VRTX 0.61, PFE 0.60, AMGN 0.48; 60d to 10-30). See S-122.
Replay (my calc, 05-01 → 10-29): Healthcare LM next-day o→c −0.40% (n 48, hit 46%).
Source: 2026-11-02 11:00 report

VRTX in line, flat AH. Tue: PFE BMO (implied ±5.2% vs TRAI 1.78%; ρ BMY .73, MRK .66, REGN .60), AMGN AMC (±4.8% vs 2.74%). Report

REGN is the sole LM name (16:49 run); ABT is an MR fade-short. PFE +1.57% AH before its Tue BMO print (no news found); VRTX +1.24% AH on a raised FY revenue guide. AMGN Tue AMC (ABT ρ 0.45, REGN 0.48) matters for Wednesday. Report

MRNA Q3: revenue $1,313M (+29% YoY), NI $162M, diluted EPS $0.38; FY26 revenue growth raised to 15%–25%; YE cash guide $8.1–$8.3B incl. ~$2.6B convert proceeds (Newswire issuer) [V-P].
TRAI SM healthcare residuals still suspended: REGN/PFE/LLY/GILD/VRTX. MRNA cluster 20 — treat as context, not automatic peer inheritance (intl COVID-driven growth; PFE clearest overlap hypothesis).
Company note: MRNA. Source: 2026-11-06 09:00 Fri open.

TMO ~+1.7% / AMGN mixed early into 10:00 live-rule window; not validated MR edge under STRESS+VIX9D/VIX>1 (S-144). Report.

HIMS Q3 Mon 2026-11-09 AMC; call 5:00 p.m. ET (Hims IR, Oct 12, 2026) [V-P].
TRAI avg \|gap\| 6.85% (0.82 ATR), max 13.49%. Thu bar −9.75% then Fri ~11:18 ET Yahoo ~+4.3%. Cluster 16 with AFRM/SOFI (avgRho 0.624) — fintech-adjacent, not classic large-pharma.
Company note: HIMS. Source: 2026-11-06 11:00 Mon gap stack.

Live case (~15:09 ET): MRNA BMO afternoon ~+10% (overruns hist avg |gap| 3.28%); TMO tools singleton ~+2.3%; cluster-5 large pharma roughly flat-to-soft (PFE still ~−1.7%); REGN singleton soft green ~+0.7%; XBI ~+2.5% vs XLV ~flat. VIX ~24.6 (still >22).
Correlation homes (asOf 11-05): cluster 5 n=9 avg ρ 0.633 (ABBV/AMGN/BMY/GILD/JNJ/LLY/NVO/PFE/VRTX); REGN cluster 38 singleton; TMO cluster 48 singleton; MRNA+MRK cluster 20 avg ρ 0.754; HIMS cluster 16 (AFRM/SOFI) — Mon AMC handoff only, already in S-145.
SM flag mismatch: 8:58 run still tags Healthcare ×5 REGN/PFE/LLY/GILD/VRTX even though REGN is a correlation singleton — label error parallel to S-146/147/148.
Thu crush: secondary profit-taking / valuation narratives only; no verified company-specific Thu 8-K for LLY/GILD/PFE/REGN. REGN Eylea HD competition is older Q3-call context (Trefis 11-05), not new Thu news.
MRNA: do not fade huge positive overrun (S-006); do not reactivate SM (S-141); ≠ automatic read-through to cluster-5 residuals.
Proposal S-149: split Healthcare SM/MR risk by correlation cluster (cluster-5 vs REGN vs TMO tools vs MRNA/MRK). Actionable Fri trading: NO.
Company notes: MRNA · TMO · REGN · PFE · LLY · GILD · VRTX · AMGN.
Source: 2026-11-06 15:00 healthcare split.